Bide Pharmatech (SH:688073) Xin Lang Cai Jing·2025-09-01 03:19Company Overview - Bid Pharma is located in Yangpu District, Shanghai, and was established on April 27, 2007. The company went public on October 11, 2022. Its main business focuses on the front end of new drug research and development, providing innovative drug molecular building blocks and scientific reagents [1][2]. Financial Performance - For the first half of 2025, Bid Pharma achieved a revenue of 628 million yuan, representing a year-on-year growth of 17.91%. The net profit attributable to shareholders was 73.41 million yuan, showing a year-on-year increase of 41.60% [2]. - Since its A-share listing, Bid Pharma has distributed a total of 258 million yuan in dividends [3]. Stock Performance - As of September 1, Bid Pharma's stock price increased by 2.34%, reaching 68.68 yuan per share, with a total market capitalization of 6.242 billion yuan. The stock has risen by 42.19% year-to-date, with a 2.25% increase over the last five trading days, 14.95% over the last 20 days, and 48.18% over the last 60 days [1]. - The stock's trading volume on September 1 was 61.0887 million yuan, with a turnover rate of 2.11% [1]. Shareholder Structure - As of June 30, 2025, the number of shareholders increased to 3,782, a rise of 4.76%. The average number of circulating shares per person decreased by 4.55% to 11,431 shares [2]. - Among the top ten circulating shareholders, notable changes include a decrease in holdings by China Europe Medical Health Mixed A and an increase by Agricultural Bank of China Medical Health Stock [3].